Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category

anti-Omalizumab ELISA Kit (ab237664)

Key features and details

  • Sample type: Plasma, Serum
  • Detection method: Colorimetric
  • Assay type: Sandwich (qualitative)
  • Reacts with: Human

You may also be interested in

Product image
Anti-Jagged1 antibody [EPR4290] - BSA and Azide free (ab184785)
Product image
Anti-TNFSF18/GITRL antibody [EPR23451-119] - BSA and Azide free (ab272696)
Product image
Anti-Eph receptor A2 antibody (ab196887)
Product image
Anti-Wnt2b antibody [EPR13386] (ab178418)

Overview

  • Product name

    anti-Omalizumab ELISA Kit
    See all Omalizumab kits
  • Detection method

    Colorimetric
  • Sample type

    Serum, Plasma
  • Assay type

    Sandwich (qualitative)
  • Assay duration

    Multiple steps standard assay
  • Species reactivity

    Reacts with: Human
  • Product overview

    anti-Omalizumab ELISA Kit (ab237664) is a highly specific and sensitive kit designed for the in vitro qualitative determination of antibody against Omalizumab in biological matrices such as human serum and plasma.


    Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Omalizumab is used to treat severe, persistent asthma. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.

  • Platform

    Microplate

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 96 tests
    Assay Buffer 1 x 12ml
    Micro ELISA Plate 1 unit
    Negative Control 1 x 0.5ml
    Peroxidase Conjugate 1 x 12ml
    Plate sealers 2 units
    Positive Control 1 x 0.25ml
    Stop Solution 1 x 12ml
    TMB substrate 1 x 12ml
    Wash buffer (20X) 1 x 50ml
  • Relevance

    Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persistent asthma.
  • Alternative names

    • Xolair

Images

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to anti-Omalizumab ELISA Kit (ab237664)

  •  
  • Product image

    Omalizumab ELISA Kit (ab237650)

    Applications:

Clear all

Recently viewed products

  •  
  • Product image

    Anti-Tropomyosin 3 antibody [3D5AH3AB4] (ab113692)

  •  
  • Product image

    Anti-S100A4 antibody [S100A4/1481] (ab218511)

  •  
  • Product image

    Anti-ADH5 antibody [EPR12885(B)] (ab177932)

  •  
  • Product image

    Anti-NUP50 antibody [EPR9525] (ab151567)

  •  
  • Product image

    Anti-Frizzled 8 antibody [EPR7308(2)] (ab155093)

  •  
  • Product image

    Anti-ADAMTS1 antibody [EPR23324-45] (ab276133)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.